Combining options in metastatic prostate cancer

Research output: Contribution to journalComment/debate

Abstract

Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

Original languageEnglish (US)
JournalNature Reviews Urology
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Combining options in metastatic prostate cancer'. Together they form a unique fingerprint.

  • Cite this